Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.59 |
| ▸ | PIK3C2B | O00750 | 9/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | HCK | P08631 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.53 |
| ▸ | PRKDC | P78527 | 1/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24338963 | 0.92 | PIK3CD (0.64) | PIK3CDPIK3CGPIK3C2BABL1EGFR | |
| SCHEMBL16701497 | 0.84 | PIK3CD (0.60) | PIK3CDPIK3CGPIK3C2BABL1EGFR | |
| SCHEMBL16701527 | 0.79 | PIK3CD (0.62) | PIK3CDPIK3CGPIK3C2BABL1EGFR | |
| SCHEMBL16701439 | 0.79 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3C2BABL1EGFR | |
| SCHEMBL16701520 | 0.79 | PIK3CD (0.73) | PIK3CDPIK3CGPIK3C2B | |
| SCHEMBL16702636 | 0.78 | PIK3CD (0.55) | PIK3CDPIK3CGPIK3C2B | |
| SCHEMBL16701877 | 0.78 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3C2B | |
| SCHEMBL16701651 | 0.78 | PIK3CD (0.60) | PIK3CDPIK3CGPIK3C2BEGFR | |
| SCHEMBL16702077 | 0.78 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3C2BEGFR | |
| SCHEMBL23287715 | 0.77 | PIK3C2B (0.55) | PIK3CDPIK3CGPIK3C2BABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2015069441-A1 | PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK) | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 8/4885PIK3C2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.